TOP TEN perturbations for 1427_g_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1427_g_at
Selected probe(set): 203761_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1427_g_at (203761_at) across 6672 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample

Relative Expression (log2-ratio):4.880604
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal plasmocytoid dendritic cell sample
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):4.0091763
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):3.4159088
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)

Relative Expression (log2-ratio):-3.2686462
Number of Samples:2 / 2
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (dysgerminoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.2024317
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)

Relative Expression (log2-ratio):3.1422052
Number of Samples:2 / 2
Experimental CNS cancer study 1 (PDX; glioma, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted).
Control CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted).

precursor-B-ALL study 1 (t(12;21)(p12,q22)) / normal bone marrow sample

Relative Expression (log2-ratio):-3.051816
Number of Samples:58 / 74
Experimental precursor-B-ALL study 1 (t(12;21)(p12,q22))
Bone marrow samples of patients with precursor B-ALL (t(12;21)(p12,q22)/TEL-AML1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

T-helper activation study 1 (160min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):2.961422
Number of Samples:2 / 2
Experimental T-helper activation study 1 (160min)
Alloantigen specific helper T-cells were stimulated for 160min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

T-helper activation study 1 (180min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):2.939911
Number of Samples:2 / 2
Experimental T-helper activation study 1 (180min)
Alloantigen specific helper T-cells were stimulated for 180min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.

T-helper activation study 1 (140min) / unstimulated helper T-cell sample

Relative Expression (log2-ratio):2.932293
Number of Samples:2 / 2
Experimental T-helper activation study 1 (140min)
Alloantigen specific helper T-cells were stimulated for 140min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors.
Control unstimulated helper T-cell sample
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors.